|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (ST2) are very interesting biomarkers for heart failure and myocardial fibrosis.
|
31622239 |
2020 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, α1-antitrypsin and lectin-like oxidized low-density-lipoprotein receptor-1 seem to represent two good markers in HF and therapeutic targets, whereas galectin-3 does not.
|
31782085 |
2020 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We undertook metabolomic and lipidomic phenotyping of a cohort of heart failure (HF) patients and utilized Multiple Regression Analysis (MRA) to identify associations to CPET and HFBio test performance (peak oxygen consumption (Peak VO2), oxygen uptake efficiency slope (OUES), exercise duration, and minute ventilation-carbon dioxide production slope (VE/VCO2 slope), as well as the established HF biomarkers of inflammation C-reactive protein (CRP), beta-galactoside-binding protein (galectin-3), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP)).
|
31220103 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is involved in fibrosis and heart failure.
|
31772609 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Circulating galectin-3 (Gal-3) is elevated and significantly correlates with all-cause and cardiovascular mortality in patients with heart failure.
|
30477951 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
CT-1 (cardiotrophin-1) and Gal-3 (galectin-3) are increased in HF and associated with myocardial fibrosis.
|
30612490 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 was not associated with either HF with reduced EF or HF with preserved EF.
|
31645163 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize recent progress in research on galectin-3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
|
30372548 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Salivary Gal-3 concentrations were significantly higher (p < 0.05) in patients with HF who subsequently experienced the primary endpoint compared to those who did not.
|
31598750 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We examined the association of arterial stiffness with galectin-3 levels in patients with HF of ischemic etiology.
|
29968538 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The goal of this study is to determine the cardiac localization and the time-course of galectin-3 expression in heart failure after viral inoculation with EMCV.
|
30673749 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Following the recommendation of natriuretic peptides (B-type natriuretic peptide and N-terminal-proBNP), many other biomarkers have been thoroughly studied to reflect different pathophysiological processes (such as fibrosis, inflammation, myocardial injury, and remodeling) in HF and some of them (like cardiac troponins, soluble suppression of tumorigenesis-2, and galectin 3) have subsequently been recommended to aid in the diagnosis and prognostication in HF.
|
31183637 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate the relationship between the presence of fragmented QRS (fQRS) on electrocardiogram (ECG) and plasma galectin-3 levels in patients with heart failure (HF) and severely decreased left ventricular ejection fraction (LVEF ≤ 35%).
|
31155816 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Gal-3 is an independent predictor of mortality and HF post-MI.
|
31072572 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the circulating decreased miR-1 and increased miR-21 expression are associated with NT-proBNP and galectin-3 levels in acute HF + DM.
|
31109008 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, ROC curve analysis suggested galectin-3 as a promising biomarker for diagnosis and HF and clinical severity.
|
31514240 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Correction to: The potential prognostic utility of salivary galectin-3 concentrations in heart failure.
|
31823039 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent clinical studies have shown that galectin-3 is a prognostic indicator in patients with coronary heart disease and in patients with heart failure.
|
30378236 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess perindopril and a galectin-3 inhibitor (modified citrus pectin, MCP) for their effects on ventricular remodeling and myocardial fibrosis in rabbits with ischemic heart failure.
|
30967790 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated plasma galectin-3 levels, a biomarker associated with myocardial fibrosis, are also associated with adverse cardiovascular events, including heart failure.
|
30721387 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is a mediator of profibrotic pathways and is associated with an increased incidence of heart failure.
|
29861319 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is implicated in the pathogenesis of heart failure and is also influenced by ageing.
|
31392851 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, CK-MB, sST2, and Gal-3 exhibited a modest diagnostic performance for HF, with an AUC of 0.709, 0.711, and 0.777, respectively.
|
30829708 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, only Gal-3 was the independent predictor of HF development at one-year observation.
|
31687050 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, inhibition of galectin‑3 by intravenous tail vein injection of a galectin‑3‑targeting short hairpin RNA‑expressing vector during hypertension‑induced heart failure in Dahl hypertensive rats increased rat survival and body weight.
|
29286090 |
2018 |